Bimekizumab Safety in Patients With Moderate to Severe Plaque Psoriasis: Analysis of Pooled Data from up to Three Years of Treatment in Phase 2 and 3 Clinical Trials. J of Skin 2022, 6 (6), s66. https://doi.org/10.25251/skin.6.supp.66.